The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience

Journal of Thoracic and Cardiovascular Surgery

Volumn 144, Issue 4, 2012, Pages 762-770

  Braunwald, Eugene ^a   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; PRAVASTATIN; STREPTOKINASE; THALLIUM 201;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMORBIDITY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DISEASE SEVERITY; EXERCISE TEST; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HUMAN; MORBIDITY; MULTICENTER STUDY (TOPIC); OXYGEN CONSUMPTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERFUSION WEIGHTED IMAGING; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84866395864     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.07.001     Document Type: Editorial

References (42)

1. R. Tennant, and C.J. Wiggers The effect of coronary occlusion on myocardial contraction Am J Physiol 112 1935 351 361
2. H.L. Blumgart, R. Gilligan, and M.J. Schlesinger Experimental studies on the effect of temporary occlusion of coronary arteries. II. The production of myocardial infarction Am Heart J 22 1941 374 389
3. E. Braunwald, J.W. Covell, P.R. Maroko, and J. Ross Jr. Effect of drugs and of counterpulsation on myocardial oxygen consumption Circulation 40 Suppl IV 1969 220 228
4. P.R. Maroko, J.K. Kjekshus, B.E. Sobel, T. Watanabe, J.W. Covell, and J. Ross Jr. Factors influencing infarct size following experimental coronary artery occlusion Circulation 43 1971 67 82
5. P.R. Maroko, and E. Braunwald Modification of myocardial infarction size after coronary occlusion Ann Intern Med 79 1973 720 733
6. E.I. Chazov, L.S. Mateeva, and A.V. Mazaev Intracoronary administration of fibrinolysin in acute myocardial infarction Ter Arkh 48 1976 8 19
7. J.E. Markis, M. Malagold, J.A. Parker, K.J. Silverman, W.H. Barry, and A.V. Als Myocardial salvage after intracoronary thrombolysis with streptokinase in acute myocardial infarction: assessment of intracoronary thallium-201 N Engl J Med 305 1981 777 782
8. The TIMI Study Group. Braunwald E (Chairman). The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932-6.
9. The TIMI Study Group. Braunwald E (Chairman): Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med. 1989;320:618-27.
10. R. Roberts, W.J. Rogers, H.S. Mueller, C.T. Lambrew, D.J. Diver, and H.C. Smith Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study Circulation 83 1991 422 437
11. D.A. Morrow, E.M. Antman, A. Sayah, K.C. Schuhwerk, R.P. Giugliano, and J.A. deLemos Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation MI: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial J Am Coll Cardiol 40 2002 71 77
12. E.M. Antman, D.A. Morrow, C.H. McCabe, S.A. Murphy, M. Ruda, and Z. Sadowski Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 2006 1477 1488
13. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, and P. Theroux Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
14. J.L. Mega, E. Braunwald, S.D. Wiviott, J.-P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 54 63
15. The TIMI III B Investigators. Braunwald E. (Chairman): Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction. Results of the TIMI III B Trial. Circulation. 1994;89:1545-56.
16. C.P. Cannon, W.S. Weintraub, L.A. Demopoulos, R. Vicari, M.J. Frey, and N. Lakkis Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 2001 1879 1887
17. E.M. Antman, C.H. McCabe, E.P. Gurfinkel, A.G.G. Turpie, P.J.L.M. Bernink, and D. Salein Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Circulation 100 1999 1593 1601
18. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2005
19. S.D. Wiviott, E. Braunwald, C.H. McCabe, I. Horvath, M. Keltai, and J.P. Herrman Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial Lancet 371 2008 1353 1363
20. S.D. Wiviott, E. Braunwald, D.J. Angiolillo, S. Meisel, A.J. Dalby, and F.W.A. Verheugt Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
21. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk, S.A. Murphy, A. Budaj, and S. Varshavsky Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
22. B.M. Scirica, D.A. Morrow, H. Hod, S.A. Murphy, L. Belardinelli, and C.M. Hedgepeth Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652
23. D.A. Morrow, B.M. Scirica, B.R. Chaitman, D.K. McGuire, S.A. Murphy, and E. Karwatowska-Prokopczuk Evaluation of glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial Circulation 119 2009 2032 2039
24. D.A. Morrow, E. Braunwald, M.P. Bonaca, S.F. Ameriso, A.J. Dalby, and M.P. Fish Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
25. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, and R. Belder Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
26. K.K. Ray, C.P. Cannon, C.H. McCabe, R. Cairns, A.M. Tonkin, and F.M. Sacks Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol 46 2005 1405 1410
27. E.M. Antman, M. Cohen, P.J.L.M. Bernink, C.H. McCabe, T. Horacek, and G. Papuchis The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842
28. D.A. Morrow, E.M. Antman, A. Charlesworth, R. Cairns, S.A. Murphy, and J.A. deLemos TIMI risk score for ST-elevation myocardial infarction. A convenient, bedside, clinical score for risk assessment at presentation. An Intravenous nPA for Treatment of infracting Myocardium Early II Trial substudy Circulation 102 2000 2031 2037
29. D.A. Morrow, E.M. Antman, R.P. Giugliano, R. Cairns, A. Charlesworth, and S.A. Murphy A simple risk index for rapid initial triage of patients with ST elevation myocardial infarction: An InTIME II Substudy Lancet 358 2001 1571 1575
30. C.M. Gibson, S.A. Murphy, M.J. Rizzo, K.A. Ryan, S.J. Marble, and C.H. McCabe Relationship between TIMI frame count and clinical outcomes after thrombolytic administration Circulation 99 1999 1945 1950
31. C.M. Gibson, C.P. Cannon, S.A. Murphy, K.A. Ryan, R. Mesley, and S.J. Marble Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs Circulation 101 2000 125 130
32. E.M. Antman, M.J. Tanasijevic, B. Thompson, M. Schactman, C.H. McCabe, and C.P. Cannon Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes N Engl J Med 335 1996 1342 1349
33. D.A. Morrow, C.P. Cannon, N. Rifai, M.J. Frey, R. Vicari, and N. Lakkis Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction. Results from a randomized trial JAMA 286 2001 2405 2412
34. J.A. de Lemos, D.A. Morrow, J.H. Bentey, T. Omland, M.S. Sabatine, and C.H. McCabe The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med 345 2001 1014 1021
35. M.S. Sabatine, D.A. Morrow, J.A. de Lemos, C.M. Gibson, S.A. Murphy, and N. Rifai Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide Circulation 105 2002 1760 1763
36. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
37. J.L. Mega, W. Hochholzer, A.L. Frelinger 3rd, M.J. Kluk, D.J. Angiolillo, and D.J. Kereiakes Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
38. C.P. Cannon, R.P. Giugliano, M.A. Blazing, R.A. Harrington, J.L. Peterson, and C.M. Sisk Design and rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
39. C.T. Ruff, R.P. Giugliano, E. Antman, S.E. Crugnale, T. Bocanegra, and M. Mercuri Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next Generation in atrial fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
40. M.L. O'Donoghue, E. Braunwald, H.D. White, P. Serruys, G. Steg, and J. Hochman Study design and rationale for the Stabliization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome Am Heart J 162 2011 613 619 epub Sep 15
41. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study Am Heart J 162 2011 818 825
42. P. Kohli, N. Desai, R.P. Giugliano, J.B. Kim, R. Somaratne, and F. Huang Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy Clin Cardiol 35 2012 385 391